Dear Customers, Colleagues, and Collaborators: At Newormics, we recognize that combating the spread of this new virus requires a global community effort. As we navigate this uncharted landscape together with you, our first concern is to express best wishes for the safety and security of yourselves and your families. We want to be in touch Read more about COVID-19 UPDATE[…]
Early larval stages of C. elegans (L1 to L3 and Dauer) have always been among the hardest to immobilize and image successfully, due to their tiny size and difficulties with using conventional anesthetics and time-consuming mounting methods. To help researchers solve these problems, Newormics is launching two new devices in our vivoChip®-2x range: vivoChip®-2x L1-L2, Read more about Newormics launches new vivoChips for early stage worms[…]
The research of Newormics is featured in a special report in the July 2019 issue of DDNews in an article titled “Phenotypic finery: Microscopy meets the molecular in the search for phenotypic impacts in drug screening”. This article reviews cutting-edge research in drug discovery using novel microscopy and image analysis technologies to screen potential drug Read more about DDNews features Newormics in their latest issue in a special report on drug screening[…]
Newormics is exhibiting at the 2019 UK C. elegans meeting at Imperial College London on September 16th. Come meet us and view our latest imaging solutions there. We will also have a special laboratory demo day, kindly hosted by Dr. Michalis Barkoulas at Imperial College London on September 17th. The demo will allow attendees to Read more about Newormics at the 2019 UK C. elegans meeting[…]
Newormics was awarded an SBIR Phase I grant from the National Institute of Environmental Health Sciences (NIEHS) for the project “A Large-Scale Microfluidics Imaging Platform for High-Throughput Toxicity Testing using Canine Intestinal Organoids”. Currently, toxicology studies require a large number of animal testing to identify better and safer drug candidates. In an attempt to reduce Read more about Newormics awarded an SBIR Phase I grant from the NIEHS[…]
Newormics is exhibiting at the 22nd International C. elegans Conference at UCLA, Los Angeles from 20th June – 24th June. Come and meet the team here at our booth.
Newormics was selected for the NIH I-Corps April-June 2019 cohort. Over the course of the I-Corps program, the team had conversations with over 100 stakeholders in the field. This helped the company gather vital market research to understand the needs and pain points of potential customers, and improve Newormics product lines The program finale was Read more about Newormics selected for the NIH I-Corps[…]
Newormics was awarded an SBIR Phase I grant from the National Institute of Mental Health (NIMH) for the project “A multi-well plate format microfluidic immobilization chip for high-content imaging of whole animals”. Advancements in precise genetic manipulation have helped biologists to identify new drug-targets and in vivo disease mechanisms using small animal models, such as Read more about Newormics awarded SBIR Phase I grant from the NIMH[…]
